Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report.

IF 1.8 4区 医学 Q2 MEDICINE, GENERAL & INTERNAL
Arina Martynchyk, Cameron Wellard, Eliza Chung, Simran K Bhopal, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Erica M Wood, Eliza A Hawkes, Mary A Anderson
{"title":"Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report.","authors":"Arina Martynchyk, Cameron Wellard, Eliza Chung, Simran K Bhopal, Zoe K McQuilten, Stephen P Mulligan, Stephen Opat, Erica M Wood, Eliza A Hawkes, Mary A Anderson","doi":"10.1111/imj.70037","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.</p><p><strong>Aims: </strong>Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).</p><p><strong>Methods: </strong>This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.</p><p><strong>Results: </strong>Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively.</p><p><strong>Conclusion: </strong>The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.</p>","PeriodicalId":13625,"journal":{"name":"Internal Medicine Journal","volume":" ","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2025-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Internal Medicine Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/imj.70037","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Treatment of chronic lymphocytic leukaemia (CLL) has evolved significantly with the advent of targeted agents. Real-world analysis of patients with CLL provides a better understanding of treatment efficacy and toxicity and informs planning of future trials; however, Australasian studies are limited.

Aims: Here we describe the demographics, disease characteristics, treatment and outcome for CLL patients enrolled in the Australia and New Zealand Lymphoma and Related Diseases Registry (LaRDR).

Methods: This study included 365 patients aged ≥18 years with CLL diagnosed between January 2016 and May 2023.

Results: Median age at diagnosis was 68 years, with 65% being male. Median follow-up was 15.2 months (range 0-78). 11q, 13q, 17p deletions and trisomy 12 were detected in 12%, 54%, 11% and 14% respectively. During the period of follow-up, 38% of patients commenced first-line therapy. The use of Bruton's Tyrosine Kinase inhibitors and B-cell lymphoma 2 inhibitors increased more than 10-fold following regulatory approval in 2020. Two-year progression-free and overall survival, measured from commencement of first-line therapy, were 67% (95% CI 55-76) and 87% (95% CI 78-93) respectively.

Conclusion: The increasing use of targeted agents largely reflected availability; however, continuing use of chemoimmunotherapy following regulatory approval of targeted agents was noted in 29% of patients in 2022.

求助全文
约1分钟内获得全文 求助全文
来源期刊
Internal Medicine Journal
Internal Medicine Journal 医学-医学:内科
CiteScore
3.50
自引率
4.80%
发文量
600
审稿时长
3-6 weeks
期刊介绍: The Internal Medicine Journal is the official journal of the Adult Medicine Division of The Royal Australasian College of Physicians (RACP). Its purpose is to publish high-quality internationally competitive peer-reviewed original medical research, both laboratory and clinical, relating to the study and research of human disease. Papers will be considered from all areas of medical practice and science. The Journal also has a major role in continuing medical education and publishes review articles relevant to physician education.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信